Adverse event signal analysis of type Ib MET tyrosine kinase inhibitors based on food and drug administration adverse event reporting system
The study highlights differences in the safety profiles of Type Ib MET TKIs, underscoring the need for further regulatory review and possible updates to product labels to better inform clinicians and patients.
Authors
- Xiangpeng Li (ORCID: https://orcid.org/0000-0002-4230-5676)
- Binbin Qu
- Junyu Wang (ORCID: https://orcid.org/0009-0009-3981-5884)
- Rong Ma (ORCID: https://orcid.org/0000-0002-0792-2812)
Institutions
- Qingdao University (CN)
- Affiliated Hospital of Qingdao University (CN)
- Qingdao Municipal Hospital (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-04-03
- DOI
- https://doi.org/10.1080/14740338.2025.2487158
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00